Larimar Therapeutics, Inc. (LRMR) stock
LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.02+0.32 (+11.85%)
Close on Nov 13, 2026Market cap $313.73MP/E –Yield –
Larimar Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Larimar Therapeutics's total debt was $6.75M at Mar 31, 2020. For fiscal 2019 it was $8.46M, down 44.3% from the year before. The highest annual figure on record is $20.00M in fiscal 2017.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $8.46M | -44.3% |
| FY2018 | Dec 31, 2018 | $15.19M | -24.1% |
| FY2017 | Dec 31, 2017 | $20.00M | +479.2% |
| FY2015 | Dec 31, 2015 | $3.45M | -44.1% |
| FY2014 | Dec 31, 2014 | $6.18M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2020 | Mar 31, 2020 | $6.75M | -50.1% |
| Q4 FY2019 | Dec 31, 2019 | $8.46M | -44.3% |
| Q3 FY2019 | Sep 30, 2019 | $10.17M | -39.6% |
| Q2 FY2019 | Jun 30, 2019 | $11.85M | -35.9% |
| Q1 FY2019 | Mar 31, 2019 | $13.53M | -32.9% |
| Q4 FY2018 | Dec 31, 2018 | $15.19M | -24.1% |
| Q3 FY2018 | Sep 30, 2018 | $16.84M | +1303.7% |
| Q2 FY2018 | Jun 30, 2018 | $18.50M | – |
| Q1 FY2018 | Mar 31, 2018 | $20.16M | – |
| Q4 FY2017 | Dec 31, 2017 | $20.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.20M | – |
See a number that looks wrong?